List view / Grid view
10 June 2016 | By Victoria White, Digital Content Producer
Data from the largest study of its kind confirm the long-term safety profile of Novartis’ Revolade in adults with chronic immune thrombocytopenia...
10 June 2016 | By Victoria White, Digital Content Producer
A Phase III trial shows daratumumab in combination with lenalidomide and dexamethasone achieved a 63% reduction in the risk of disease progression or death...
10 June 2016 | By
New data show promising results for venetoclax in patients with chronic lymphocytic leukaemia who have relapsed or become refractory (R/R) to treatment...
10 June 2016 | By Victoria White, Digital Content Producer
In a Phase Ib study, bimekizumab showed fast and sustained efficacy on disease activity measures in both skin and joints and was well-tolerated...
Lilly and Incyte have announced new data for baricitinib in rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology (EULAR 2016).
9 June 2016 | By Victoria White, Digital Content Producer
Data demonstrating long-term comparable efficacy, safety and immunogenicity of Benepali (etanercept) and Flixabi (infliximab) have been presented at EULAR...
9 June 2016 | By Victoria White, Digital Content Producer
The Phase I/II study was designed to demonstrate the safety and tolerability of GS010 in 15 patients with Leber’s Hereditary Optic Neuropathy...
9 June 2016 | By Victoria White, Digital Content Producer
The programme will enable patients with serious fungal infections in EU states where the treatment is not yet commercially available to access isavuconazole...
9 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced positive first results from a Phase II investigating the efficacy and safety of AMG 334 (erenumab) in chronic migraine prevention...
9 June 2016 | By Victoria White, Digital Content Producer
AGI is to acquire the rights, outside the US, to AstraZeneca’s portfolio of anaesthetics for an upfront consideration of $520 million...
8 June 2016 | By Mandy Parrett, Editorial Assistant
Global biopharma company, Bristol-Myers Squibb, will present new data and offer insights into the field of rheumatoid arthritis at the Annual European Congress of Rheumatology (EULAR 2016) this week.
8 June 2016 | By Victoria White, Digital Content Producer
Patients with SLE experienced a significantly greater response to treatment with Benlysta administered via subcutaneous injection compared to placebo...
8 June 2016 | By Victoria White, Digital Content Producer
The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis...
8 June 2016 | By Victoria White, Digital Content Producer
Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
8 June 2016 | By Victoria White, Digital Content Producer
The combination is approved for the first-line treatment of adult patients with non-squamous NSCLC with EGFR-activating mutations...
